Physician profile
Kumar P Dalla
NPI 1841291903
$14,200.32
in general payments reported to CMS, 2019-2025
26 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 83% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $1,244 · 2021: $2,793 · 2022: $3,622 · 2023: $1,212 · 2024: $1,562 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,811.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $6,800.09 | 2019-2022 | |
| Genentech USA, INC. | $2,309.46 | 2019-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $736.39 | 2022-2025 | Syfovre |
| Abbvie INC. | $604.90 | 2022-2025 | Ozurdex |
| Glaukos Corporation | $504.48 | 2019-2025 | Idosetr, Istent Infinite, Idose |
| Allergan, INC. | $436.82 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $349.70 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $338.48 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Astellas Pharma US INC | $303.44 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $250.60 | 2019-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $242.64 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $209.02 | 2022-2025 | Eylea, Eylea Hd |
| Carl Zeiss Meditec USA, INC. | $186.89 | 2021 | |
| Coherus Oncology, INC. | $181.06 | 2022-2023 | |
| Harrow Eye, LLC | $173.10 | 2025 | Iheezo, Triesence |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $125.15 | 2019-2021 | |
| Biogen, INC. | $72.10 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $69.33 | 2020-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $61.16 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.87 | 2020-2021 | |
| Amgen INC. | $52.48 | 2024-2025 | Tepezza |
| Genentech, INC. | $41.02 | 2019-2020 | |
| Horizon Therapeutics Plc | $35.80 | 2023 | Tepezza |
| Sandoz INC. | $34.00 | 2024 | Cimerli |
| Aerie Pharmaceuticals, INC. | $18.91 | 2021 | |
| Topcon Healthcare, INC. | $10.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$120,257.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Dalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.